A Canadian phase II study evaluating the efficacy of rituximab in the management of patients with relapsed/refractory thrombotic thrombocytopenic purpura

George, 1994, Chronic idiopathic thrombocytopenic purpura, N Engl Med, 331, 1207, 10.1056/NEJM199411033311807 Tsai, 2006, Current concepts in thrombotic thrombocytopenic purpura, Annu Rev Med, 57, 419, 10.1146/annurev.med.57.061804.084505 George, 2006, Thrombotic thrombocytopenic purpura, N Engl J Med, 354, 1927, 10.1056/NEJMcp053024 Furlan, 1998, Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremia syndrome, N Engl J Med, 339, 1578, 10.1056/NEJM199811263392202 Tsai, 1998, Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura, N Engl Med, 22, 1585, 10.1056/NEJM199811263392203 Veyradier, 2001, Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases, Blood, 98, 1765, 10.1182/blood.V98.6.1765 Mori, 2002, Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity, Transfusion, 42, 572, 10.1046/j.1537-2995.2002.00100.x Vesely, 2003, ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients, Blood, 102, 60, 10.1182/blood-2003-01-0193 Coppo, 2004, Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement, Medicine (Baltimore), 83, 233, 10.1097/01.md.0000133622.03370.07 Zheng, 2004, Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura, Blood, 103, 4043, 10.1182/blood-2003-11-4035 Peyvandi, 2004, von Willebrand factor cleaving protease (ADAMTS13) and ADAMTS13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura, Br J Haematol, 127, 433, 10.1111/j.1365-2141.2004.05217.x Coppo, 2006, Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura, Br J Haematol, 132, 66, 10.1111/j.1365-2141.2005.05837.x Tsai, 2001, Inhibitors of von Willebrand Factor cleaving protease in thrombotic thrombocytopenic purpura, Clin Lab, 47, 387 Jin, 2008, Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse, Br J Haematol, 141, 651, 10.1111/j.1365-2141.2008.07107.x Rock, 1991, Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura, N Engl Med, 325, 393, 10.1056/NEJM199108083250604 George, 2000, How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, Blood, 96, 1223, 10.1182/blood.V96.4.1223 Rock, 2000, Management of thrombotic thrombocytopenic purpura, Br J Haematol, 109, 496, 10.1046/j.1365-2141.2000.01941.x Tsai, 2003, Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura, J Am Soc Nephrol, 14, 1072, 10.1097/01.ASN.0000060805.04118.4C Allford, 2003, Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias, Br J Haematol, 120, 556, 10.1046/j.1365-2141.2003.04049.x Sallah, 2004, Rituximab in patients with refractory thrombotic thrombocytopenic purpura, J Thromb Haemost, 2, 834, 10.1111/j.1538-7836.2004.00678.x Ahmad, 2004, Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP), Am J Hematol, 77, 171, 10.1002/ajh.20166 Fakhouri, 2005, Efficiency of curative and prophylactic treatment with Rituximab in ADAMTS13-sdeficient thrombotic thrombocytopenic purpura: a study of 11 cases, Blood, 106, 1932, 10.1182/blood-2005-03-0848 Scully, 2007, Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following Rituximab is associated with a reduction in IgG antibodies to ADAMTS13, Br J Haematol, 136, 451, 10.1111/j.1365-2141.2006.06448.x Heidel, 2007, Addition of Rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia, Thromb Haemost, 97, 228, 10.1160/TH06-09-0499